Mucopolysaccharidosis (MPS) are a group of rare genetic disorders caused by
deficiency in the activity of specific lysosomal enzymes required for the
degradation of glycosaminoglycans (GAGs). A defect in the activity of these
enzymes will result in the abnormal accumulation of GAGs inside the lysosomes of
most cells, inducing progressive cellular damage and multiple organ failure. DNA
samples from 70 patients with biochemical diagnosis of different MPSs genotypes
confirmed by Sanger sequencing were used to evaluate a Next Generation
Sequencing (NGS) protocol. Eleven genes related to MPSs were divided into three
different panels according to the clinical phenotype. This strategy led to the
identification of several pathogenic mutations distributed across all exons of
MPSs-related genes. We were able to identify 96% of all gene variants previously
identified by Sanger sequencing, showing high sensitivity in detecting different
types of mutations. Furthermore, new variants were not identified, representing
100% specificity of the NGS protocol. The use of this NGS approach for genotype
identification in MPSs is an attractive option for diagnosis of patients. In
addition, the MPS diagnosis workflow could be divided in a two-tier approach:
NGS as a first-tier followed by biochemical confirmation as a second-tier.
We demonstrate that an SNP in the AMH gene is associated with infertility in endometriosis, whereas several SNPs in the GDF-9 gene and the - 482A G SNP in the AMHR2 gene were found to be unrelated.
Emerging clinical data demonstrates that COVID-19, the disease caused by SARS-CoV2, is a syndrome that variably affects nearly every organ system. Indeed, the clinical heterogeneity of COVID-19 ranges from relatively asymptomatic to severe disease with death resultant from multiple constellations of organ failures. In addition to genetics and host characteristics, it is likely that viral dissemination is a key determinant of disease manifestation. Given the complexity of disease expression, one major limitation in current animal models is the ability to capture this clinical heterogeneity due to technical limitations related to murinizing SARS-CoV2 or humanizing mice to render susceptible to infection. Here we describe a murine model of COVID-19 using respiratory infection with the native mouse betacoronavirus MHV-A59. We find that whereas high viral inoculums uniformly led to hypoxemic respiratory failure and death, lethal dose 50% (LD50) inoculums led to a recapitulation of most hallmark clinical features of COVID-19, including lymphocytopenias, heart and liver damage, and autonomic dysfunction. We find that extrapulmonary manifestations are due to viral metastasis and identify a critical role for type-I but not type-III interferons in preventing systemic viral dissemination. Early, but not late treatment with intrapulmonary type-I interferon, as well as convalescent serum, provided significant protection from lethality by limiting viral dissemination. We thus establish a Biosafety Level II model that may be a useful addition to the current pre-clinical animal models of COVID-19 for understanding disease pathogenesis and facilitating therapeutic development for human translation.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.